Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Oct;48(10):904–907. doi: 10.1136/jcp.48.10.904

Use of dried blood spots for the detection and confirmation of HTLV-I specific antibodies for epidemiological purposes.

S P Parker 1, M B Taylor 1, A E Ades 1, W D Cubitt 1, C Peckham 1
PMCID: PMC502943  PMID: 8537486

Abstract

AIMS--To modify and evaluate a gelatin particle agglutination test that could provide a sensitive, specific and inexpensive method for the detection of HTLV-I antibody in dried blood spot samples (DBS) collected on filter paper. METHODS--A set of 26 reference samples confirmed as HTLV-I antibody positive were assembled from patients with tropical spastic paraparesis or adult T cell leukaemia and blood donors. Serum samples and simulated antibody positive dried blood spot eluates were tested using the Serodia assay together with two confirmatory tests: HTLV BLOT 2.3, a western blot, and Select-HTLV, an enzyme immunoassay (EIA). Both confirmatory tests use synthetic peptides to differentiate between antibodies to HTLV-I and -II. The modified Serodia assay was then used to test anonymously 10,135 DBS collected from neonates from London. Samples reactive in the modified Serodia test producing a positive result were titrated to an end point and confirmed as before. RESULTS--All 26 eluates made from simulated DBS derived from positive reference samples were identified as positive by the modified Serodia HTLV-I test and were confirmed as anti-HTLV-I positive by EIA. Two eluates derived from relatively low titre reference samples gave indeterminate results on western blotting. Screening of the 10,135 neonatal DBS resulted in six repeat reactives, five of which were confirmed. The remaining reactive sample gave an indeterminate result on western blotting and there was insufficient eluate for testing by EIA. The overall seroprevalence of HTLV-I in this population was 0.05% (five of 10,135). CONCLUSION--The modified Serodia HTLV-I assay provides a sensitive, specific and inexpensive (10 pence/test) method for screening large numbers of DBS. The format of the assay makes it ideally suited for simultaneous screening of antibodies to HIV-1, HIV-2 and HTLV-I using semi-automated equipment.

Full text

PDF
904

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ades A. E., Parker S., Berry T., Holland F. J., Davison C. F., Cubitt D., Hjelm M., Wilcox A. H., Hudson C. N., Briggs M. Prevalence of maternal HIV-1 infection in Thames regions: results from anonymous unlinked neonatal testing. Lancet. 1991 Jun 29;337(8757):1562–1565. doi: 10.1016/0140-6736(91)93260-g. [DOI] [PubMed] [Google Scholar]
  2. Banatvala J. E., Chrystie I. L., Palmer S. J., Kenney A. Retrospective study of HIV, hepatitis B, and HTLV-I infection at a London antenatal clinic. Lancet. 1990 Apr 7;335(8693):859–860. doi: 10.1016/0140-6736(90)90977-d. [DOI] [PubMed] [Google Scholar]
  3. Bastian I., Dent J., McFarlane R., Karopoulos A., Way B. HTLV-I among Northern Territory blood donors. Med J Aust. 1993 Jul 5;159(1):7–12. doi: 10.5694/j.1326-5377.1993.tb137693.x. [DOI] [PubMed] [Google Scholar]
  4. Bastian I., Hinuma Y., Doherty R. R. HTLV-I among Northern Territory aborigines. Med J Aust. 1993 Jul 5;159(1):12–16. doi: 10.5694/j.1326-5377.1993.tb137694.x. [DOI] [PubMed] [Google Scholar]
  5. Beilke M. A. Detection of HTLV-I in clinical specimens. J Virol Methods. 1992 Nov;40(2):133–144. doi: 10.1016/0166-0934(92)90062-i. [DOI] [PubMed] [Google Scholar]
  6. Bhigjee A. I., Kelbe C., Haribhai H. C., Windsor I. M., Hoffmann M. H., Modi G., Bill P. L., Becker W. B., Singh B., Engelbrecht S. Myelopathy associated with human T cell lymphotropic virus type I (HTLV-I) in natal, South Africa. A clinical and investigative study in 24 patients. Brain. 1990 Oct;113(Pt 5):1307–1320. doi: 10.1093/brain/113.5.1307. [DOI] [PubMed] [Google Scholar]
  7. Brennan M., Runganga J., Barbara J. A., Contreras M., Tedder R. S., Garson J. A., Tuke P. W., Mortimer P. P., McAlpine L., Tosswill J. H. Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donors in north London. BMJ. 1993 Nov 13;307(6914):1235–1239. doi: 10.1136/bmj.307.6914.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Catalan F., Ly T. D., Milovanovic A. Communiqué: étude des trousses Sérodia-HIV et Sérodia-ATLA FUJIREBIO-MILES. Ann Biol Clin (Paris) 1990;48(3):207–209. [PubMed] [Google Scholar]
  9. Catovsky D., Greaves M. F., Rose M., Galton D. A., Goolden A. W., McCluskey D. R., White J. M., Lampert I., Bourikas G., Ireland R. Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet. 1982 Mar 20;1(8273):639–643. doi: 10.1016/s0140-6736(82)92200-0. [DOI] [PubMed] [Google Scholar]
  10. Couroucé A. M., Pillonel J., Lemaire J. M., Maniez M., Brunet J. B. Seroepidemiology of HTLV-I/II in universal screening of blood donations in France. AIDS. 1993 Jun;7(6):841–847. doi: 10.1097/00002030-199306000-00013. [DOI] [PubMed] [Google Scholar]
  11. Cruickshank J. K., Rudge P., Dalgleish A. G., Newton M., McLean B. N., Barnard R. O., Kendall B. E., Miller D. H. Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain. 1989 Aug;112(Pt 4):1057–1090. doi: 10.1093/brain/112.4.1057. [DOI] [PubMed] [Google Scholar]
  12. Fujino R., Kawato K., Ikeda M., Miyakoshi H., Mizukoshi M., Imai J. Improvement of gelatin particle agglutination test for detection of anti-HTLV-I antibody. Jpn J Cancer Res. 1991 Apr;82(4):367–370. doi: 10.1111/j.1349-7006.1991.tb01856.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gallo D., Diggs J. L., Hanson C. V. Evaluation of two commercial human T-cell lymphotropic virus western blot (immunoblot) kits with problem specimens. J Clin Microbiol. 1994 Sep;32(9):2046–2049. doi: 10.1128/jcm.32.9.2046-2049.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gessain A., Barin F., Vernant J. C., Gout O., Maurs L., Calender A., de Thé G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985 Aug 24;2(8452):407–410. doi: 10.1016/s0140-6736(85)92734-5. [DOI] [PubMed] [Google Scholar]
  15. Hobbs J. R., Davis J. A. Serum gamma-G-globulin levels and gestational age in premature babies. Lancet. 1967 Apr 8;1(7493):757–759. doi: 10.1016/s0140-6736(67)91369-4. [DOI] [PubMed] [Google Scholar]
  16. Ichimaru M., Ikeda S., Kinoshita K., Hino S., Tsuji Y. Mother-to-child transmission of HTLV-1. Cancer Detect Prev. 1991;15(3):177–181. [PubMed] [Google Scholar]
  17. Inostroza J., Diaz P., Saunier C. Prevalence of antibodies to HTLV-1 in South American Indians (Mapuches) from Chile. Scand J Infect Dis. 1991;23(4):507–508. doi: 10.3109/00365549109075102. [DOI] [PubMed] [Google Scholar]
  18. Jogessar V. B., de Bruyn C. C., Bhigjee A. I., Naicker V. L., Bill P. L., Tait D. Adult T-cell leukaemia/lymphoma associated with HTLV-I in Natal. S Afr Med J. 1992 May 16;81(10):528–529. [PubMed] [Google Scholar]
  19. Karopoulos A., Silvester C., Dax E. M. A comparison of the performance of nine commercially available anti-HTLV-I screening assays. J Virol Methods. 1993 Nov;45(1):83–91. doi: 10.1016/0166-0934(93)90142-e. [DOI] [PubMed] [Google Scholar]
  20. Khabbaz R. F., Onorato I. M., Cannon R. O., Hartley T. M., Roberts B., Hosein B., Kaplan J. E. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992 Feb 6;326(6):375–380. doi: 10.1056/NEJM199202063260604. [DOI] [PubMed] [Google Scholar]
  21. Lal R. B., Brodine S., Kazura J., Mbidde-Katonga E., Yanagihara R., Roberts C. Sensitivity and specificity of a recombinant transmembrane glycoprotein (rgp21)-spiked western immunoblot for serological confirmation of human T-cell lymphotropic virus type I and type II infections. J Clin Microbiol. 1992 Feb;30(2):296–299. doi: 10.1128/jcm.30.2.296-299.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lal R. B., Heneine W., Rudolph D. L., Present W. B., Hofhienz D., Hartley T. M., Khabbaz R. F., Kaplan J. E. Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. J Clin Microbiol. 1991 Oct;29(10):2253–2258. doi: 10.1128/jcm.29.10.2253-2258.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mochizuki M., Watanabe T., Yamaguchi K., Takatsuki K., Yoshimura K., Shirao M., Nakashima S., Mori S., Araki S., Miyata N. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res. 1992 Mar;83(3):236–239. doi: 10.1111/j.1349-7006.1992.tb00092.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murphy E. L., Figueroa J. P., Gibbs W. N., Brathwaite A., Holding-Cobham M., Waters D., Cranston B., Hanchard B., Blattner W. A. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1989 Oct 1;111(7):555–560. doi: 10.7326/0003-4819-111-7-555. [DOI] [PubMed] [Google Scholar]
  25. Okochi K., Sato H., Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang. 1984;46(5):245–253. doi: 10.1111/j.1423-0410.1984.tb00083.x. [DOI] [PubMed] [Google Scholar]
  26. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986 May 3;1(8488):1031–1032. doi: 10.1016/s0140-6736(86)91298-5. [DOI] [PubMed] [Google Scholar]
  27. Salker R., Tosswill J. H., Barbara J. A., Runganga J., Contreras M., Tedder R. S., Parra-Mejia N., Mortimer P. P. HTLV-I/II antibodies in UK blood donors. Lancet. 1990 Aug 4;336(8710):317–317. doi: 10.1016/0140-6736(90)91856-6. [DOI] [PubMed] [Google Scholar]
  28. Saxinger W., Blattner W. A., Levine P. H., Clark J., Biggar R., Hoh M., Moghissi J., Jacobs P., Wilson L., Jacobson R. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. Science. 1984 Sep 28;225(4669):1473–1476. doi: 10.1126/science.6089348. [DOI] [PubMed] [Google Scholar]
  29. Taniguchi S., Maekawa N., Yashiro N., Hamada T. Detection of human T-cell lymphotropic virus type-1 proviral DNA in the saliva of an adult T-cell leukaemia/lymphoma patient using the polymerase chain reaction. Br J Dermatol. 1993 Nov;129(5):637–641. doi: 10.1111/j.1365-2133.1993.tb00503.x. [DOI] [PubMed] [Google Scholar]
  30. Tosswill J. H., Parry J. V., Weber J. N. Application of screening and confirmatory assays for anti-HTLV-I/II in U.K. populations. J Med Virol. 1992 Mar;36(3):167–171. doi: 10.1002/jmv.1890360304. [DOI] [PubMed] [Google Scholar]
  31. Verdier M., Denis F., Leonard G., Sangare A., Patillaud S., Prince-David M., Essex M. Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera. J Clin Microbiol. 1990 Sep;28(9):1988–1993. doi: 10.1128/jcm.28.9.1988-1993.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Weber J. N., Banatvala N., Clayden S., McAdam K. P., Palmer S., Moulsdale H., Tosswill J., Dilger P., Thorpe R., Amann S. HTLV-1 infection in Papua New Guinea: evidence for serologic false positivity. J Infect Dis. 1989 Jun;159(6):1025–1028. doi: 10.1093/infdis/159.6.1025. [DOI] [PubMed] [Google Scholar]
  33. White P. M. Comparison of assays for antibody to HTLVI. J Clin Pathol. 1988 Jun;41(6):700–702. doi: 10.1136/jcp.41.6.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet. 1994 Jan 22;343(8891):213–216. doi: 10.1016/s0140-6736(94)90994-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES